Could a simple vaccine slash COPD attacks?
NCT ID NCT07508644
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a single dose of the RSV vaccine (Arexvy) can reduce moderate-to-severe COPD flare-ups in people who have frequent attacks. Researchers will enroll 320 high-risk patients aged 50+ and follow them for one year. Half will get the vaccine plus standard care, the other half standard care alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSV vaccine (Arexvy)
- What this could lead to
- If it works, this could reduce the number of serious COPD flare-ups by at least 20%, offering a new way to manage the disease.
- What could go wrong
- This is a Phase 4 trial, but it's open-label (no placebo), which can bias results. The 20% reduction target is modest, and the vaccine may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prince of Wales Hospital
Shatin, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may curb antibiotic overuse in COPD attacks
- Can pressurized breathing boost mucus clearance in lung disease?
- HIV and hidden health risks: a major study probes the link
- Can a new model help botswana shield infants from RSV?
- Can tracking early COPD reveal ways to halt its progression?
- Smart inhaler coach: can an app perfect your breathing technique?